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reminder were 2.15 times (95% CI = 1.73 to 2.61) more likely
to have an inﬂuenza immunization. CONCLUSIONS: Although
inﬂuenza immunization rates remain low, IVR reminders
produce higher rates of inﬂuenza immunizations and increase
patient adherence in older adults.
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OBJECTIVES: Retreatment of acute infections can often be high
thereby increasing treatment costs. This study examined the
retreatment rates of acute otitis media in patients with tympa-
nostomy tubes (AOMT) within the Louisiana Medicaid popula-
tion. METHODS: Louisiana Medicaid claims data for
2000–2002 were retrospectively reviewed for episodes of
AOMT. Tympanostomy tube (t-tube) patients were identiﬁed
using CPT codes from an index period of January 1, 2000
through June 30, 2000. AOMT patients were followed for 24
months from their respective index dates. Episodes of AOMT
were then identiﬁed from the t-tube sample group using ICD-
9-CM codes. An episode started with the ﬁrst antibiotic claim
between one day before or two days after an ICD-9-CM code
for AOMT and ended 21 days later. Retreatment was deﬁned as
the presence of another antibiotic claim between days 3 and days
21 of an episode of care. Only antibiotics commonly used in the
treatment of AOMT were considered in the retreatment analy-
sis. Retreatment rates were calculated on an overall (per episode)
basis and by antibiotic. RESULTS: There were 5934 episodes of
AOMT care identiﬁed within the dataset of which 1381 required
retreatment resulting in an overall retreatment rate of approxi-
mately 23%. Some of the antibiotics commonly prescribed in the
treatment of AOMT are presented in rank order relative to their
retreatment rates: ciproﬂoxacin HCL and hydrocortisone (12%),
cephalexin (17%), oﬂoxacin (26%), amoxicillin (28%), amoxi-
cillin potassium clavulanate (32%), sulfamethoxazole trimetho-
prim (32%), azithromycin (32%), clarithromycin (33%),
cefdinir (33%), and cefprozil (36%). CONCLUSIONS: The
retreatment rate of AOMT in the Louisiana Medicaid popula-
tion was high with approximately 1 out of 4 episodes requiring
retreatment. Retreatment rates also varied considerably between
antibiotic therapies. Careful consideration of AOMT antibiotic
therapy by clinicians may reduce retreatment rates thereby low-
ering the associated cost of AOMT treatment in the Louisiana
Medicaid program.
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OBJECTIVE: To better understand the consequences of branded
macrolide therapy, we assessed rates of re-treatment following
the use of azithromycin or clarithromycin among outpatients
diagnosed with common respiratory-tract infections in the 
California Medicaid (“Medi-Cal”) program. METHODS: We
employed a retrospective cohort design using administrative
claims data for a 20% random sample of California Medicaid
recipients. We selected outpatients diagnosed with common
upper or lower respiratory-tract infections, including acute otitis
media, acute pharyngitis, acute sinusitis, chronic bronchitis, or
community-acquired pneumonia during an ofﬁce visit between
February 1, 1997 and May 31, 2002. Patients were prescribed
either azithromycin or clarithromycin as treatment following
diagnosis. The main study outcome was the ﬁlling of another
prescription for an antibiotic (i.e., “retreatment”) within 30 days
following receipt of branded macrolide therapy. For each infec-
tion type, logistic regression was used to estimate the rate of
retreatment for the two initial macrolides, adjusting for age.
RESULTS: We identiﬁed 6196 patients diagnosed with acute
otitis media, 3794 with community-acquired pneumonia, 2716
diagnosed with pharyngitis, 1354 with chronic bronchitis, and
1162 with sinusitis who received one of the two macrolides of
interest. Sixteen (acute otitis media) to 20% (sinusitis) of patients
failed treatment with their initial macrolide. Relative to clar-
ithromycin, azithromycin was associated with a signiﬁcantly
lower retreatment rate when used in patients with acute otitis
media (OR: 0.63; 95% CI: 0.50 to 0.80; P < 0.0001) or chronic
bronchitis (0.70; 0.50 to 0.98; P = 0.039). The likelihood of
retreatment (azithromycin relative to clarithromycin) did not
differ for patients with pharyngitis (0.96; 0.74 to 1.26; P =
0.783), sinusitis (1.03; 0.75 to 1.42; P = 0.842), or community-
acquired pneumonia (0.93; 0.77 to 1.13; P = 0.450). CON-
CLUSIONS: Compared to clarithromycin, azithromycin is
associated with a lower retreatment rate when used for acute
otitis media or chronic bronchitis in this Medicaid population.
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OBJECTIVE: The purpose of this study was to examine the 
epidemiology of Hepatitis C (HCV) in the Louisiana Medicaid
population. HCV is estimated to have infected 170 million
people worldwide. In many countries, it is the most common
cause of chronic liver disease and is the most common indica-
tion for liver transplantation. Progression and complications of
the disease may lead to cirrhosis, liver failure, and hepatocellu-
lar carcinoma (HCC). HCV affects nearly 4 million people in the
U.S. HCV causes an estimated 10,000 to 12,000 deaths annu-
ally in the U.S. Approximately 70% of these people develop
chronic hepatitis and 20% progress to cirrhosis predisposing
them to HCC. METHODS: This study is a retrospective sec-
ondary database claims analysis. Medicaid recipients were fol-
lowed longitudinally for the years 1998, 1999, and 2000, which
consequently constitute the study period for this research. Recip-
ients were included in one of two groups based on their diag-
nosis: Infected (having HCV) and at-risk (having a diagnosis of
hemophilia, cocaine addiction, drug abuse, cirrhosis, hepatitis B,
and HIV or received hemodialysis). Only recipients who were
continuously eligible throughout the 3-year study period were
included in the study. RESULTS: The prevalence of HCV in the
LA Medicaid population during the study period was 7.08 per
1000. Among the at-risk population, the recipients with a diag-
nosis hemophilia or drug abuse had the highest prevalence. There
were 18,286 recipients in the at-risk group while 2128 recipients
were classiﬁed in the infected group. The infected group con-
sisted of 1151 females (54%) and racial breakdown showed that
1183 (55%) African Americans had HCV. Similar results were
obtained when at-risk groups were analyzed. CONCLUSIONS:
Most frequently occurring comorbidities in the infected popula-
tion, were asthma, chest pain, urinary tract infection and bron-
chitis. About 30 % of the recipients in the at-risk group had been
tested for HCV.
